Details for New Drug Application (NDA): 214194
✉ Email this page to a colleague
The generic ingredient in DEFERASIROX is deferasirox. There are twenty drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the deferasirox profile page.
Summary for 214194
| Tradename: | DEFERASIROX |
| Applicant: | Amneal |
| Ingredient: | deferasirox |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | GRANULE;ORAL | Strength | 180MG | ||||
| Approval Date: | Feb 9, 2021 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | GRANULE;ORAL | Strength | 360MG | ||||
| Approval Date: | Feb 9, 2021 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | GRANULE;ORAL | Strength | 90MG | ||||
| Approval Date: | Aug 2, 2021 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
